Go to the USUHS home page
ABOUT AFRRI   |   A to Z INDEX   |   CONTACT US
   

About AFRRI
  Our products
  A to Z index
  Contact us

Biodosimetry Tools

Emergency Response Resources
  Advisory team
  Other resources

Managing Radiation Casualties
POLICIES
  Depleted uranium
  Potassium iodide
  Prussian blue
PUBLICATIONS
  Radiation patient treatment
  Managing radiological casualties
  Response to nuclear detonation
      • 1st Edition (Jan 2009)
      • 2nd Edition (Jun 2010)
  NCRP recommendations
  Consequences of nuclear warfare

Medical Effects of Ionizing Radiation
  In-person course
  Online course
  Schedule, fees, registration
  Course resources
  Brochure
  » What is ionizing radiation? «
  » Veterans' radiation exposure «

Product Quick List
  Exposure assessment tools
  Forms
  Guidance

Publications
  Books/book chapters
  Contract reports
  Journal articles/supplements
  Reports/report chapters
  Scientific reports
  Special publications
  Technical reports

Register AFRRI Products

Research Programs
  Biodosimetry
  Combined Injury: Radiation with
      Other Insults

  Internal Contamination and
      Metal Toxicity

  Countermeasure Development

2014 AFRRI Seminars

USU Dept. of Radiation Biology
You are here:  HOME  >  What's New  >  Peer review validates AFRRI research of measuring radioprotection drug by liquid chromatography
PREVIOUS HEADLINES

New handbook guides
medical decisions in a
radiological emergency


Dept. of Homeland Security
medical experts visit AFRRI


Ceremony welcomes
new AFRRI director
(2010)

Unprecedented growth marks
AFRRI director's tenure


NRC Commissioner
tours AFRRI


Special assignment:
The Vancouver Olympics


American Nuclear Society
unveils historic-landmark plaque


Historic landmark plaque
to be installed at defense lab


AFRRI receives historic
award from American
Nuclear Society


Iraq researchers
tour AFRRI


AFRRI awarded nuclear
historic landmark status


AFRRI leaders, other research
reactor experts convene
at annual conference


Research pioneer
touched lives, influenced
future of radiation science


Former AFRRI
scientific director was
pioneer in radiation research


Researchers share latest
radiation-effects findings
with military medical community


AFRRI scientific director
elected to NCRP


Scientists deliberate
on diagnostics for
partial-body irradiation


New software to aid
treatment decisions during
radiation exposure incidents


International experts on
radiation exposure assessment
to convene at AFRRI


Ceremony marks change
of director at AFRRI
(2006)

FDA clears 5-AED for
human clinical studies


New collaboration
will develop radiation
countermeasures


Training for the unthinkable

AFRRI employees participate
in MASCAL drill


EPA awards AFRRI scientists
with highest honor


DoD commends AFRRI
for response to terrorism


Ceremony welcomes
new AFRRI director
(2003)

Revised handbook expands
casualty management
information


Peer review validates
AFRRI research of
measuring radioprotection
by liquid chromatography


MEIR course available
on handy card-size disc


AFRRI launches software
for radiation casualty
management


Chernobyl liquidators'
teeth may link radiation
dose and disease


Individual exposure
takes heat in
radiation study


Russian scientists take
different path in search
for radioprotectors

Peer review validates AFRRI research of measuring radioprotection drug by liquid chromatography

 
BETHESDA, Md., Jan. 24, 2003—AFRRI researchers have validated a method of measuring WR1065—the active, radioprotective drug derived from the metabolism of amifostine—and WR-33278, its derivative symmetrical disulfide, in the blood by liquid chromatography with electrochemical detection (LC-ECD). Another independent researcher validated the method.

The AFRRI research team—James A. Pendergrass Jr., Venkataraman Srinivasan, K. Sree Kumar, William E. Jackson III, and Thomas M. Seed—used WR-2721 in a biodegradable, slow-release pellet designed for injection under the skin in laboratory mice. They studied whether the radioprotection of WR-2721 in mice correlates with the levels of WR-1065 found in the blood but, they wrote in their research paper, they needed "a reliable and sensitive method of analysis" to detect these compounds.

"Although WR-2721 is an excellent radioprotective drug," the researchers wrote in the Journal of AOAC International (vol. 85, No. 3, 2002, pages 551-554), "its use is limited because of toxicity. One approach to limiting toxicity is to slow down its release into the bloodstream."

Several laboratories use LC-ECD to measure WR-1065 and WR-33278, but the AFRRI research team was unable consistently to repeat in its laboratory the results reported in the literature. "We just weren't able to reproduce what some of those labs reported in the literature," Mr. Pendergrass said.

However, "I found a published report where a lab added cysteamine to their mobile phase and, voilà, I tried it and got reproducible results. Because I had tried so many methods and failed until I hit upon the current one, I wanted to publish a report that proved that my method was independently reproducible using similar equipment and the same mobile phase."

In the reported AFRRI experiments, "the measurements were repeatable day after day, and the accuracy and precision of each day's measurements were very acceptable," Mr. Pendergrass said. After he and his colleagues developed a method that was consistently reproducible, they then sought to show that another laboratory could duplicate their method.

The AFRRI researchers asked Dr. Wayne A. Kleinman of the American Health Foundation in Valhalla, NY, to reproduce their experiment, and he duplicated the thiol and disulfide measurements with similar accuracy and precision.

 

 

 

 

 

 

 

 

 

 

 

TOP OF PAGE